Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region

European Journal of Cancer Part A

Volumn 32, Issue 12, 1996, Pages 2155-2163

  Petrarca, C ^a   Rughetti, A ^a   Rahimi, H ^a   Agostini, F ^a   Turchi, V ^a   Ghetti, C Apollonj ^a   Scambia, G ^b   Frati, L ^a,c   Nuti, M ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c Mediterranean Institute of Neuroscience   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

epitope mapping; human antibodies; immune response; polymorphic epithelial mucin; tumour associated antigens

Indexed keywords

EPITOPE; MUCIN; POLYMORPHIC EPITHELIAL MUCIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; OVARY CANCER; PRIORITY JOURNAL;

ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL SEPARATION; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; GLYCOSYLATION; HUMANS; OVARIAN NEOPLASMS; REPETITIVE SEQUENCES, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 0030298428     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00254-7     Document Type: Article

References (40)

1. 1. Hilkens J, Ligtenberg MJL, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992, 17, 359-363.
2. 2. Lanzavecchia A. Identifying strategies for immune intervention. Science 1994, 260, 937-944.
3. 3. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990, 265, 15286-15293.
4. 4. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989, 43, 1072-1076.
5. 5. Gendler SJ, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988, 263, 12820-12823.
6. 6. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987, 47, 5476-5482.
7. 7. Lalani EN, Berdichevsky F, Boshell M, et al. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem 1991, 266, 15420-15426.
8. 8. Xing PX, Prenzoska J, Quelch K, McKenzie IFC. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res 1992, 52, 2310-2317.
9. 9. Ding L, Lalani EN, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC-1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC-1 gene. Cancer Immun Immunother 1993, 36, 9-17.
10. 10. Rughetti A, Turchi V, Apollonj Ghetti C, et al. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993, 53, 2457-2459.
11. 11. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 1994, 54, 2856-2860.
12. 12. Gourevitch MM, Mensdorff-Pouilly SV, Litvinov SV, et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995, 72, 934-938.
13. 13. Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996, 32A, 1325-1331.
14. 14. Band LD, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989, 86, 7159-7163.
15. 15. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991, 51, 2908-2916.
16. 16. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical of one-, two-, and three-tandem repeats of human mucin (MUC-1) protein core. Cancer Res 1993, 53, 5386-5394.
17. 17. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res 1995, 55, 2257-2261.
18. 18. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF. Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981, 28, 17-21.
19. 19. Nuti M, Turchi V, Rughetti A, et al. Characterisation of monoclonal antibody 436 recognising the ARG-PRO-ALA-PRO sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells. Int J Biol Markers 1992, 7, 71-79.
20. 20. Geysen HM, Rodda SJ, Mason TJ, Tribbick G, Schoofs PG. Strategies for epitope design using peptide synthesis. J Immunol Meth 1987, 102, 259-274.
21. 21. Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJB. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 1990, 62, 795-802.
22. 22. Burchell J, Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC-1 gene product. Epith Cell Biol 1993, 2, 155-162.
23. 23. Kuan SF, Byrd JC, Kim YS. Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells. J Biol Chem 1989, 264, 19271-19277.
24. 24. Parmiani G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 1993, 14, 536-538.
25. 25. Moudgil KD, Sercarz EE. Can anti-tumor immune responses discriminate between self and nonself? Immunol Today 1994, 15, 353-355.
26. 26. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995, 82, 13-17.
27. 27. Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. A short sequence, within the tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 1989, 44, 691-696.
28. 28. Nishimori I, Perini F, Mountjoy KP, et al. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. Cancer Res 1994, 54, 3738-3744.
29. 29. Stadie TR, Chai W, Lawson AM, Byfield PG, Hanish FG. Studies on the order and site specificity of Ga1NAc transfer to MUC1 tandem repeats by UDP-Ga1NAc: polypeptide N-acetyl-galactosaminyltransferase from milk or mammary carcinoma cells. Eur J Biochem 1995, 229, 140-147.
30. 30. Pupa SM, Ménard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993, 53, 5864-5866.
31. 31. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994, 54, 16-20.
32. 32. Punt CJA, Barbuto JAM, Zhang H, Grimes WJ, Hatch KD, Hersh EM. Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 1994, 38, 225-232.
33. 33. Croce MV, Price MR, Segal-Eiras AE. Expression of monoclonal-antibody-denned antigens in fractions isolated from human breast carcinomas and patients' serum . Cancer Immun Immunother 1995, 40, 132-137.
34. 34. Lubin R, Schlichtholz B, Bengoufa D, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993, 53, 5872-5876.
35. 35. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52, 4168-4174.
36. 36. Manson LA. Does antibody-dependent epitope masking permit progressive tumor growth in the face of cell-mediated cytotoxicity? Immunol Today 1991, 12, 352-355.
37. 37. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985, 314, 537-539.
38. 38. Davidson HW, Watts C. Epitope-directed processing of specific antigen by B lymphocytes. J Cell Biol 1989, 109, 85-92.
39. 39. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995, 181, 1957-1963.
40. 40. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995, 155, 4766-4774.